GlobeNewswire by notified

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Share

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

RIYADH, Saudi Arabia, May 11, 2024 (GLOBE NEWSWIRE) -- Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at Harvard University. In his address, Dr. Al Fayyadh showcased the KFSH&RC’s journey since its inception in Riyadh almost five decades ago, highlighting how it has significantly reduced the need for patients to travel abroad for medical care. KFSH&RC has evolved into a premier provider of tertiary healthcare services and today offers cutting-edge treatments for heart diseases, tumors, organ transplantation, and genetic disorders.

Dr. Al Fayyadh discussed KFSH&RC's transformation into an independent, non-profit foundation. This move, he indicated, aligns with the organization's strategic vision to become a global healthcare innovation leader, emphasizing excellence, innovation, and investment in cutting-edge technology to tackle global health challenges.

"The Saudi Leadership has outlined a clear vision for KFSH&RC, mandated by a royal decree transitioning the hospital into an independent Sui Generis, non-profit foundation," stated His Excellency, Dr. Al Fayyadh.

He further highlighted that this transformation seeks to elevate global healthcare standards through increased independence and flexibility. This shift will allow KSFH&RC to optimize existing services, pursue new opportunities, and direct resources toward initiatives that promote human health and well-being both within the Kingdom and internationally. Ultimately, this move reinforces KFSH&RC's dedication to patient-centered excellence.

Dr. Al Fayyadh pointed out that KFSH&RC envisions itself as a leader in maximizing the value of healthcare spending, adhering to evidence-based practices to ensure optimal patient outcomes. It seeks to remain at the forefront of global healthcare innovation, with initiatives designed to increase health equity and access worldwide. To achieve this, KFSH&RC will continue to invest in cutting-edge medical facilities, advanced diagnostic equipment, and state-of-the-art treatment technologies. Building on existing progress in areas like CAR T-cell therapy, robotic surgeries, organ transplants, and personalized medicine, the institution aims to achieve global competitiveness. This will be further supported by fostering an exceptional workforce, pursuing Nobel Prize-caliber breakthroughs, and strengthening strategic international collaborations.

Dr. Al Fayyadh joined a panel discussion focusing on the evolving landscape of the healthcare sector and the positive outcomes of KFSH&RC’s ongoing transformation in patient care. He also addressed current challenges and anticipated future developments within the healthcare sector, emphasizing the profound impact of the hospital's innovations on global healthcare advancement. Additionally, Dr. Al Fayyadh highlighted the effective role of the hospital's transformative initiatives in aligning with the objectives of the Health Sector Transformation Program and Saudi Vision 2030.

KFSH&RC is recognized as one of the leading global institutions that provide specialized healthcare, drive innovation, and serve as an advanced medical research and education hub. It is dedicated to developing medical technologies and elevating healthcare standards worldwide, forging partnerships with leading local, regional, and international institutions to deliver world-class services in clinical, research, and educational domains.

For the second year running, KFSH&RC has retained its status as the leading institution in the Kingdom and ranks 20th globally among the top 250 academic medical centers worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance, and has been ranked among the world's top 250 hospitals by Newsweek Magazine.

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister - may God protect him - to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to "Brand Finance." Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine "Newsweek."

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27-fa87-49ac-b72b-ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee-20a5-4328-bf00-e036bc3350fd

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Udnævnelse af ny CFO24.5.2024 20:05:00 CEST | pressemeddelelse

MEDDELELSE NR. 269 Udnævnelse af ny CFO Bestyrelsen i ChemoMetec har med virkning fra 1. juli 2024 ansat Kim Nicolajsen som ny CFO. Kim Nicolajsen kommer fra en tilsvarende stilling som CFO i den familieejede virksomhed Rohde Nielsen. Han er statsautoriseret revisor og har tidligere arbejdet for KPMG og EY. Bestyrelsen har samtidig indgået aftale med selskabets nuværende CFO Niels Høy Nielsen om, at han fratræder sin stilling samtidig med Kim Nicolajsens tiltræden. Bestyrelsen vil gerne takke Niels Høy Nielsen for hans indsats i ChemoMetec og for det gode samarbejde. Direktionen i ChemoMetec vil herefter bestå af CEO Martin Helbo Behrens og CFO Kim Nicolajsen. Yderligere oplysninger Bestyrelsesformand Niels Thestrup Telefon: (+45) 3370 2000 CEO Martin Helbo Behrens Telefon: (+45) 4813 1020 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrumenter til celletælling og en lang række andre målinger. ChemoMetecs instrumenter markedsføres globalt inden for blandt andet f

Appointment of new CFO24.5.2024 20:05:00 CEST | Press release

ANNOUNCEMENT NO. 269 Appointment of new CFO The board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec. For further information Chairman of the Board Niels Thestrup Phone: (+45) 3370 2000 CEO Martin Helbo Behrens Phone: (+45) 4813 1020 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s i

Interim Report January – March 202424.5.2024 19:35:00 CEST | Press release

First quarter 2024 (compared to first quarter 2023) Net sales for the quarter amounted to MSEK 13 (13)Gross margin for the quarter decreased to 67% (74%)Operating loss amounted to MSEK -14 (-14)Earnings per share before and after dilution decreased to SEK 0.00 (-0.12) The report for January – March 2024 is available in its entirety on the following address: https://www.anoto.com/investors/reports/ For further information contact: Kevin Adeson, Chairman of the Board of Directors For more information about Anoto, visit www.anoto.com or email ir@anoto.com Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication on 24 May 2024 at 19:30 CEST. About Anoto Group Anoto is a publicly held Swedish technology company known globally for innovation in the area of infor

HiddenA line styled icon from Orion Icon Library.Eye